Ciphergen announced this week that Eric Fung has been promoted to chief scientific officer. In his new position, Fung will be responsible for setting the strategic direction of Ciphergen's clinical development programs, integrating these programs with the company's research and development efforts, and helping to drive growth in the area of predictive diagnostics, Ciphergen said.
Fung joined Ciphergen in 2000 as a lead scientist in the company's Biomarker Discovery Center laboratories, and went on to become vice president of clinical and medical affairs. He has managed many of Ciphergen's academic and pharmaceutical collaborations, Ciphergen said.
Prior to joining Ciphergen, Fung was a Howard Hughes-sponsored researcher at Stanford University. He completed an anatomic pathology internship at Stanford Medical School, and obtained his MD and PhD degree in molecular neuroscience from the Johns Hopkins University School of Medicine. In addition to working at Ciphergen, Fung also holds an adjunct assistant professor position in Johns Hopkins' department of pathology.
Genome Canada has appointed Michael Morgan as chief scientific officer.
Morgan was formerly chief executive of the Wellcome Trust Genome Campus. He graduated in biochemistry from Trinity College, Dublin, and obtained his PhD from Leicester University for studies of microbial carbohydrate metabolism. He joined the Wellcome Trust in 1983.
At the Wellcome Trust, Morgan was responsible for the development of several initiatives, including the International Human Genome Sequencing Project, the Mouse Sequencing Project, the UK Synchrotron, DIAMOND, the SNP Consortium, and the Structural Genomics Consortium.
Alfa Wassermann has appointed Dino DiCamillo as president of its proteomic technologies division.
DiCamillo joins Alfa Wassermann from Invitrogen, where he served as vice president of environmental diagnostics and vice president of commercial operations in bead-based separations. Before that, he was president of Dynal Biotech. He also spent 13 years at Applied Biosystems, and has worked for Nicolet Instruments and Bio-Rad Laboratories.
Di Camillo graduated from Lake Superior State University and received an executive MBA from Temple University.
Alfa Wassermann also appointed Mark Flocco to a newly created position as vice president of business development and marketing in its proteomics technologies division.
Flocco joins Alfa Wassermann from Bruker Daltonics, where he served as business development manager for clinical proteomics and biomarker discovery. Flocco has also worked as the Northeast regional sales manager for Ciphergen Biosystems, and he worked for eight years in sales and marketing at Beckman Coulter. In addition, Flocco has served as director of microchemistry at Princeton University.
Flocco earned a bachelor's of science in biology at Widener College in Chester, Pa.